263 related articles for article (PubMed ID: 34179212)
1. Weight Change and Predictors of Weight Change Among Patients Initiated on Darunavir/Cobicistat/Emtricitabine/Tenofovir Alafenamide or Bictegravir/Emtricitabine/Tenofovir Alafenamide: A Real-World Retrospective Study.
Emond B; Rossi C; Côté-Sergent A; Dunn K; Lefebvre P; Lafeuille MH; Donga P
J Health Econ Outcomes Res; 2021 Jun; 8(1):88-98. PubMed ID: 34179212
[No Abstract] [Full Text] [Related]
2. Body mass index increase and weight gain among people living with HIV-1 initiated on single-tablet darunavir/cobicistat/emtricitabine/tenofovir alafenamide or bictegravir/emtricitabine/tenofovir alafenamide in the United States.
Emond B; Rossi C; Côté-Sergent A; Bookhart B; Anderson D; Lefebvre P; Lafeuille MH; Donga P
Curr Med Res Opin; 2022 Feb; 38(2):287-298. PubMed ID: 34812097
[TBL] [Abstract][Full Text] [Related]
3. Weight and BMI Changes Following Initiation of Emtricitabine/Tenofovir Alafenamide Co-Formulated with Darunavir or Co-Administered with Dolutegravir in Overweight or Obese, ART-Naïve People Living with HIV-1.
Donga P; Emond B; Rossi C; Bookhart BK; Lee J; Caron-Lapointe G; Wei F; Lafeuille MH
Clinicoecon Outcomes Res; 2023; 15():579-591. PubMed ID: 37521004
[TBL] [Abstract][Full Text] [Related]
4. Treatment Patterns and Predictors of Adherence in HIV Patients Receiving Single- or Multiple-Tablet Darunavir, Cobicistat, Emtricitabine, and Tenofovir Alafenamide.
Chow W; Donga P; Côté-Sergent A; Rossi C; Lefebvre P; Lafeuille MH; Hardy H; Emond B
Patient Prefer Adherence; 2020; 14():2315-2326. PubMed ID: 33262581
[TBL] [Abstract][Full Text] [Related]
5. Brief Report: Pharmacokinetics of Bictegravir and Tenofovir in Combination With Darunavir/Cobicistat in Treatment-Experienced Persons With HIV.
Salama E; Hill L; Patel N; Best BM; Momper JD
J Acquir Immune Defic Syndr; 2021 Dec; 88(4):389-392. PubMed ID: 34285156
[TBL] [Abstract][Full Text] [Related]
6. Comparing Real-World Healthcare Costs Associated with Single-Tablet Regimens for HIV-1: The 2-Drug Regimen Dolutegravir/Lamivudine vs. Standard 3- or 4-Drug Regimens.
Priest J; Germain G; Laliberté F; Duh MS; Mahendran M; Fakih I; Oglesby A
Infect Dis Ther; 2023 Aug; 12(8):2117-2133. PubMed ID: 37552426
[TBL] [Abstract][Full Text] [Related]
7. Excessive Weight Gain: Current Antiretroviral Agents in Virologically Suppressed People with HIV.
Hsu RK; Brunet L; Fusco JS; Mounzer K; Lamori JC; Fusco GP
AIDS Res Hum Retroviruses; 2022 Oct; 38(10):782-791. PubMed ID: 35923143
[TBL] [Abstract][Full Text] [Related]
8. Real-World Analysis of Weight Gain and Body Mass Index Increase Among Patients with HIV-1 Using Antiretroviral Regimen Containing Tenofovir Alafenamide, Tenofovir Disoproxil Fumarate, or Neither in the United States.
Emond B; Rossi C; Rogers R; Lefebvre P; Lafeuille MH; Donga P
J Health Econ Outcomes Res; 2022; 9(1):39-49. PubMed ID: 35233432
[No Abstract] [Full Text] [Related]
9. Patient Satisfaction with Once-Daily Single-Tablet Darunavir, Cobicistat, Emtricitabine, and Tenofovir Alafenamide (DRV/c/FTC/TAF): A Real-World Study of Patient Self-Reported Outcomes in HIV-1-Diagnosed Adults.
LaMori J; Seignez A; Radoszycki L
Patient Prefer Adherence; 2022; 16():83-94. PubMed ID: 35058689
[TBL] [Abstract][Full Text] [Related]
10. Switching to bictegravir/emtricitabine/tenofovir alafenamide (BIC/FTC/TAF) plus darunavir/cobicistat in heavily antiretroviral-experienced, virologically suppressed HIV-infected adults receiving complex regimens.
Podzamczer D; Imaz A; Lopez-Lirola A; Knobel H; Masiá M; Fanciulli C; Hernández C; Lagarde M; Gutierrez A; Curran A; Morano L; Montero-Alonso M; Troya J; Rigo R; Casadellà M; Navarro-Alcaraz A; Ardila F; Parera M; Bernal E; Echeverria P; Estrada V; Hidalgo-Tenorio C; Macias J; Prieto P; Portilla J; Valencia E; Vivancos MJ; Rivero A
J Antimicrob Chemother; 2023 Nov; 78(11):2696-2701. PubMed ID: 37725999
[TBL] [Abstract][Full Text] [Related]
11. Brief Report: Weight Gain Following ART Initiation in ART-Naïve People Living With HIV in the Current Treatment Era.
Ruderman SA; Crane HM; Nance RM; Whitney BM; Harding BN; Mayer KH; Moore RD; Eron JJ; Geng E; Mathews WC; Rodriguez B; Willig AL; Burkholder GA; Lindström S; Wood BR; Collier AC; Vannappagari V; Henegar C; Van Wyk J; Curtis L; Saag MS; Kitahata MM; Delaney JAC
J Acquir Immune Defic Syndr; 2021 Mar; 86(3):339-343. PubMed ID: 33148997
[TBL] [Abstract][Full Text] [Related]
12. A four-drug combination oral tablet of darunavir, cobicistat, emtricitabine, and tenofovir alafenamide for the treatment of HIV-1 infection in adults.
Muccini C; Castagna A
Expert Rev Anti Infect Ther; 2023; 21(11):1167-1176. PubMed ID: 37800640
[TBL] [Abstract][Full Text] [Related]
13. Darunavir-cobicistat-emtricitabine-tenofovir alafenamide: safety and efficacy of a protease inhibitor in the modern era.
Squillace N; Bozzi G; Colella E; Gori A; Bandera A
Drug Des Devel Ther; 2018; 12():3635-3643. PubMed ID: 30464395
[TBL] [Abstract][Full Text] [Related]
14. Bictegravir/emtricitabine/tenofovir alafenamide in paediatrics: Real-life experience from a French cohort (2019-2023).
Frange P; Veber F; Burgard M; Blanche S; Avettand-Fenoel V
HIV Med; 2024 Feb; 25(2):299-305. PubMed ID: 37807595
[TBL] [Abstract][Full Text] [Related]
15. Switching to bictegravir/emtricitabine/tenofovir alafenamide maintained HIV-1 RNA suppression in participants with archived antiretroviral resistance including M184V/I.
Andreatta K; Willkom M; Martin R; Chang S; Wei L; Liu H; Liu YP; Graham H; Quirk E; Martin H; White KL
J Antimicrob Chemother; 2019 Dec; 74(12):3555-3564. PubMed ID: 31430369
[TBL] [Abstract][Full Text] [Related]
16. Treatment persistence of bictegravir/emtricitabine/tenofovir alafenamide and efavirenz + lamivudine + tenofovir disoproxil among HIV-1 patients newly starting treatment in Hunan Province in China.
Jing C; Wei T; Ning W; Fang Z; Gang X; Xingzhi W; Guoqiang Z; Min W
BMC Infect Dis; 2023 Jun; 23(1):396. PubMed ID: 37308847
[TBL] [Abstract][Full Text] [Related]
17. Efficacy, durability, and tolerability of bictegravir/emtricitabine/tenofovir alafenamide for the treatment of HIV in a real-world setting in Belgium.
Nasreddine R; Florence E; Yombi JC; Henrard S; Darcis G; Van Praet J; Vandekerckhove L; Allard SD; Demeester R; Messiaen P; Ausselet N; Delforge M; De Wit S;
HIV Med; 2023 Aug; 24(8):914-924. PubMed ID: 37038245
[TBL] [Abstract][Full Text] [Related]
18. Clinical efficacy, safety, and subjective experience based on ePRO in HIV-infected individuals administered Bictegravir/Emtricitabine/Tenofovir Alafenamide in southwest China.
Kong L; Xie X; Fu Y; Gan L; Yang X; Ma S; Long H
Immun Inflamm Dis; 2023 Aug; 11(8):e974. PubMed ID: 37647435
[TBL] [Abstract][Full Text] [Related]
19. Reasons, safety and efficacy analysis for conversion of HAART to TAF/FTC/BIC among HIV-infected patients.
Xiao J; Gao G; Ding Y; Li J; Gao C; Xu Q; Wu L; Liang H; Ni L; Wang F; Duan Y; Yang D; Zhao H
Chin Med J (Engl); 2023 Dec; 136(24):2931-2937. PubMed ID: 38032036
[TBL] [Abstract][Full Text] [Related]
20. Population Pharmacokinetic Analysis of Darunavir and Tenofovir Alafenamide in HIV-1-Infected Patients on the Darunavir/Cobicistat/Emtricitabine/Tenofovir Alafenamide Single-Tablet Regimen (AMBER and EMERALD Studies).
Ackaert O; McDougall D; Pérez-Ruixo C; Pérez-Ruixo JJ; Jezorwski J; Crauwels HM
AAPS J; 2021 Jun; 23(4):82. PubMed ID: 34100149
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
